The recent AI wave driven by tremendous ability to utilize data helps gain more knowledge from data, make valuable predictions, create novel applications (e.g., driverless cars) and improve nearly all sectors of business as well as our everyday life. This great stride is brought about by a confluence of progress in IT, and other technologies that enable generation and or collection of data, storage, handling and compute with concomitant attempts to improve sophisticated approaches to process data. In this post we explore the status of our ability to tackle the popular adage “Garbage In, Garbage Out (GIGO)” to maximize the opportunities and enable progress. This is the first of a two-part post on adopting AI at scale. Centered on the theme of GIGO, we will also explore early successes of (true and pseudo) AI-based solutions, implications for subsequent progress, preparing businesses for reaping value from these solutions and setting appropriate strategies for digital and AI transformation. We take this opportunity to highlight advantages of the approach the outcomes intelligence company ReSurfX is taking with excellent success.
This is a longer version of the post with same title at Massachusetts Technology Leadership Council (MassTLC) - published on June 20, 2022 that was also spotlighted in MassTLC Newsletter of June 22, 2022.
Once in a rare while, unexpected events leave a major impact on society such as the current COVID-19 pandemic, necessitating additional urgency to create, innovate and be more efficient. That is true for established enterprises and emerging ones alike.
ReSurfX is an ‘outcomes intelligence’ company focused on improving innovation, outcomes, and ROI of enterprises from data-intensive activities, with primary focus on healthcare (Pharma, Biotech and patient care). ReSurfX provides value through significant improvements in accuracy, robustness, novel insights, and advance prediction of outcome directions by leveraging a data-source agnostic novel machine learning (ML) approach we invented – Adaptive Hypersurface Technology (AHT). ReSurfX::vysen is an enterprise software product that delivers these functionalities.
Here we demonstrate the predictive power of AHT based functionalities through an extremely powerful SyRTOP configuration of ReSurfX::vysen product and outline several applications. The rare form of validations provided here are in the form of FDA actions based on Real World Evidence and Post Market Surveillance that are difficult to achieve even with expensive targeted studies.
Recently we added a new ‘System Response Based Triggers and Outcomes Predictor’ (SyRTOP) to our enterprise grade Decision Analytics software product ReSurfX::vysen. Here we share an exemplary result that proves the enhanced accuracy, lack of contaminating incorrect results, and many other advantages of this new solution. SyRTOP was tested on a system-wide gene expression response in liver tissue after treatment with a panel of drugs compared against a larger drug response database (Knowledge Repository) and proved to be a best in class solution as with other solutions incorporated in ReSurfX::vysen. The result is shown below.
click on the image to see at high resolution
Update: February 13, 2021: A newer article on ReSurfX::vysen in SyRTOP configuration with further improved results, powerful validations and description of components
is published on February 11, 2021. This article has some information complementary to that.
ReSurfX is an 'outcomes intelligence' company enabling better decisions. innovation, outcomes and ROI for enterprises from their data-intensive activities, with primary focus on healthcare (including Pharma, biotech and patient care). The enterprise software product ReSurfX::vysen offered by ReSurfX as SaaS leverages a novel data-source agnostic machine learning approach 'Adaptive Hypersurface Technology' (AHT) invented by Suresh Gopalan providing Artificial Intelligence (AI)-driven suite of functionalities and technology redesign solutions, including the proprietary 'Advance Outcomes Alert System'. The solutions leveraging AHT have been shown to be the best-in-class, including the SyRTOP AI predictor configuration of ReSurfX::vysen.
Large volumes of data (Big data) usually display a problem termed ‘curse of dimensionality (CoD)’. Often, many statistical practitioners will scoff at and be very circumspect of solutions that claim to do well in data analytics and decisions/outcomes that seem to overcome the curse of dimensionality (CoD). It is particularly refreshing to see that in a recent blog for MassBio that the author (Loralyn Mears) considers that CoD can be overcome – even though in the context of wondering how the recent efforts to consolidate data in Pharma as ‘data lake(s)’ and ‘stream computing’ are going to overcome CoD.
In two recently released analysis we demonstrated a never before achieved reduction of false positives by use of our product ReSurfX::vysen on a data that has been extensively studied to develop numerous analytic technologies. That data is from large-scale gene expression technology analysis – Read on.. don’t let that field of application sway your interest. This never before possible level of accuracy was made possible by a breakthrough data-source agnostic 'Adaptive Hypersurface Technology' (AHT) that ReSurfX is leveraging in data-analytics and continuing to develop. Here, we discuss the state-of-the-art in data-analytics, current thoughts and problems (from popular media and authoritative source). What does it mean for your innovation and ROI?
How can ZERO get a great ROI for your enterprise and improve your innovation potential? Big Data brings more opportunities and errors into your workflow. Robust accuracy and automatable knowledge extraction are keys to successfully leveraging this digital transformation.
Recently we showed how a ZERO from the ReSurfX::vysen product should yield a great ROI and improve innovation for your enterprise using an extensive analysis of sequencing (RNASeq). Here we repeat that excercise with Microarray data and show that the UNPRECEDENTED VALUE OBTAINED FOR RNAseq DATA IS REPLICATED to this platform as well. This is of incredible importance, given the data-source agnostic property of Adaptive Hypersurface Technology (AHT).
Recently we released a new version of our analytics product ReSurfX::vysen 2.0 – showcasing the power of our Adaptive Hypersurface Technology (AHT)™ using RNAseq and Microarray based gene expression analysis.
As we had done previously with sequencing quality control consortium (SEQC) benchmark data (RNAseq), here we carried out a similar analysis using microarray quality control consortium (MAQC) data from two sites that had each carried out analysis on the same two tissue samples with 5 replicates each. We AGAIN found that ReSurfX:: vysen:
- Identified ‘ZERO’ false positive differentially expressed gene from about 10 million calls IN 180 (EVERY within-sample 3-replicate) COMPARISON EACH INVOLVING 54,675 GENES, proving remarkable false positive control.
- Is incredibly MORE SENSITIVE AND REPRODUCIBLE THAN ANY OTHER ANALYTICS APPROACH comparing ALL POSSIBLE between-sample THREE-REPLICATE COMBINATIONS from each of the two sites. For this purpose vysen was used in over 11 million calls for differentially expressed genes across 200 comparisons.
The strength of these results from vysen are AGAIN unprecedented with enormous impact for analytics and outcomes highlighting the versatility of the data-source agnostic AHT technology despite very different raw data properties of Microarray and RNAseq data. Here we share the details of this unprecedented accuracy.
How can a ZERO from an analytics product get a great ROI and improve innovation for your enterprise?
Recently we released a new version of our analytics product ReSurfX::vysen 2.0 – initially showcasing the power of our Adaptive Hypersurface Technology (AHT)™ using RNAseq and Microarray based gene expression analysis.
Here we prove the power of vysen using unprecedented results with enormous impact for analytics and outcomes. This forms one basis for vysen being the most accurate product in the market.
We analyzed sequencing quality control consortium (SEQC) benchmark data from two sites (Mayo Clinic and Beijing Genomics Institute) that had each carried out sequencing (RNAseq) analysis on two different tissue samples with 5 replicates each. We found that ReSurfX::vysen :
- Identified ‘ZERO’ false positive differentially expressed gene from over 10 million calls IN 180 (EVERY within-sample 3-replicate) COMPARISONS EACH INVOLVING 58,051 GENES, proving remarkable false positive control.
- Is incredibly MORE SENSITIVE AND REPRODUCIBLE THAN ANY OTHER APPROACH through direct comparison, as well as comparing ALL POSSIBLE between-sample THREE-REPLICATE COMBINATIONS. This involved 200 vysen comparisons of 58,051 genes in over 11 million DEG calls.